Comparison of Short-term and Long-term Outcomes Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy in Lower Thoracic Esophageal Cancer Treatment
This study compares the short-term and long-term outcomes of Ivor-Lewis and McKeown minimally invasive esophagectomy in the treatment of lower thoracic esophageal cancer, focusing on overall postoperative complication rates.
MIE Ivor- Lewis
+ MIE McKeown
Digestive System Diseases+6
+ Digestive System Neoplasms
+ Esophageal Diseases
Treatment Study
Summary
Study start date: January 1, 2020
Actual date on which the first participant was enrolled.This study focuses on treating lower thoracic esophageal cancer and esophageal-gastric junction cancer. Traditional open surgery for these conditions often comes with high complication and mortality rates. To address this, a minimally invasive esophagectomy (MIE) was developed, which includes two main surgical approaches: MIE McKeown and MIE Ivor-Lewis. The goal of this study is to compare the safety and effectiveness of these two MIE approaches in the long and short term. This research is important as it aims to improve surgical outcomes and reduce complications for patients with these specific types of cancer. During the study, participants undergo either the MIE McKeown or MIE Ivor-Lewis procedure. The study then measures and compares the overall postoperative complication rates between the two groups. This helps determine which approach results in fewer complications and better patient outcomes. The potential benefits of participating include receiving a potentially safer and more effective surgical treatment for the specific type of cancer.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.272 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 30 to 80 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
Active ComparatorStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location